Financial Performance - Medline Inc. reported Q4 net sales of $7.8 billion, a 14.8% increase driven by higher volumes in the Medline Brand and Supply Chain Solutions segments [1][4] - Net income for Q4 fell by 37.7% to $180 million, while Adjusted EBITDA remained nearly flat at $805 million due to higher operating costs, IPO-related expenses, and tariff-related costs [2] - For the full year, net sales increased by 11.5% to $28.4 billion, supported by $2.4 billion in new customer signings, while net income decreased by 3.6% to $1.2 billion [2] Future Outlook - The CEO emphasized that the transition to a public company has strengthened Medline's foundation for sustainable long-term growth [3] - Medline introduced 2026 guidance, projecting organic sales growth between 8% and 9% [3] - Adjusted EBITDA for 2026 is expected to reach a range of $3.5 billion to $3.6 billion as the company continues to utilize its distribution footprint and broad product portfolio [3] Company Overview - Medline Inc. manufactures med-surg products serving various healthcare facilities in the US and internationally, operating through two segments: Medline Brand and Supply Chain Solutions [4]
Medline (MDLN) Q4 Net Sales Rise 14.8% to $7.8B Following Completion of IPO